



Chimerix, Inc.
Investor Relations Department
2505 Meridian Pkwy
Suite 100
Durham, NC 27713
United States

Visit IR website [↗](#)
Sign-up for Email alerts [↗](#)

NASDAQ: CMRX

Last Trade:	4.68
Trade Time:	1:02 PM ET May 22, 2017
Change:	0.00 (0.000%)
Day Range	4.65 - 4.79
52-Week Range	3.50 - 6.64
Volume	68,804


Stock information is provided by eSignal,
stock charts provided by EDGAR Online.
Stock data is delayed approximately 20
minutes.

Company Profile

Chimerix is a biopharmaceutical company dedicated to discovering, developing and commercializing medicines that improve outcomes for immunocompromised patients. Chimerix's proprietary lipid conjugate technology has produced brincidofovir; CMX157, which was licensed to ContraVir Pharmaceuticals; and earlier-stage clinical candidates. Chimerix recently announced a new clinical candidate, CMX521, for the treatment and/or prevention of norovirus.

... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

May 9, 2017

[Chimerix Announces First Quarter 2017 Financial Results](#)

May 2, 2017

[Chimerix to Announce First Quarter 2017 Financial Results on May 9, 2017](#)

Apr 20, 2017

[Chimerix to Host Annual Investor Update on April 27, 2017](#)

Mar 2, 2017

[Chimerix Announces Fourth Quarter and Full Year 2016 Financial Results](#)

Feb 28, 2017

[Chimerix to Present at Cowen and Company 37th Annual Health Care Conference](#)

Financials [\[View all \]](#)

[First Quarter Financial Results](#)

Mar 2, 2017

[Annual Report \(10-K\)](#)

May 1, 2017

[Proxy Statement \(DEF 14A\)](#)

May 9, 2017

[Quarterly Report \(10-Q\)](#)

Nov 7, 2016

[Quarterly Report \(10-Q\)](#)

Aug 8, 2016

[Quarterly Report \(10-Q\)](#)